within Pharmacolibrary.Drugs.ATC.G;

model G01AA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 500000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G01AA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Nystatin is a polyene antifungal medication primarily used to treat cutaneous, oral, vaginal, and gastrointestinal fungal infections caused by Candida species. It is not absorbed systemically from the gastrointestinal tract and is considered safe for localized fungal infections. Nystatin is approved for clinical use and widely used today for the treatment of superficial candidiasis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for nystatin are not well established in humans because the drug is not systemically absorbed when administered orally or topically. No systemic PK parameters (bioavailability, clearance, volume of distribution) can be found in the literature due to negligible absorption.</p><h4>References</h4><ol><li><p>Schäfer-Korting, M, et al., &amp; Korting, HC (1996). Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk. <i>Mycoses</i> 39(9-10) 329–339. DOI:<a href=&quot;https://doi.org/10.1111/j.1439-0507.1996.tb00149.x&quot;>10.1111/j.1439-0507.1996.tb00149.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9009654/&quot;>https://pubmed.ncbi.nlm.nih.gov/9009654</a></p></li><li><p>Knowles, S, et al., &amp; Shear, NH (1994). Metronidazole hypersensitivity. <i>The Annals of pharmacotherapy</i> 28(3) 325–326. DOI:<a href=&quot;https://doi.org/10.1177/106002809402800305&quot;>10.1177/106002809402800305</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8193418/&quot;>https://pubmed.ncbi.nlm.nih.gov/8193418</a></p></li><li><p>de Aguiar, MM, et al., &amp; Holandino, C (2010). Oral sustained release nystatin tablets for the treatment of oral candidiasis: formulation development and validation of UV spectrophotometric analytical methodology for content determination. <i>Drug development and industrial pharmacy</i> 36(5) 594–600. DOI:<a href=&quot;https://doi.org/10.3109/03639040903384729&quot;>10.3109/03639040903384729</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19954405/&quot;>https://pubmed.ncbi.nlm.nih.gov/19954405</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G01AA01;
